LungLife AI Past Earnings Performance
Past criteria checks 0/6
LungLife AI has been growing earnings at an average annual rate of 7%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 73.5% per year.
Key information
7.0%
Earnings growth rate
57.6%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | -73.5% |
| Return on equity | -56.3% |
| Net Margin | -15,403.4% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
We Think LungLife AI (LON:LLAI) Needs To Drive Business Growth Carefully
Dec 08
We Think LungLife AI (LON:LLAI) Needs To Drive Business Growth Carefully
Aug 12Here's Why LungLife AI (LON:LLAI) Must Use Its Cash Wisely
Feb 09Here's Why We're A Bit Worried About LungLife AI's (LON:LLAI) Cash Burn Situation
Oct 08Revenue & Expenses Breakdown
How LungLife AI makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -4 | 4 | 0 |
| 31 Mar 24 | 0 | -5 | 5 | 0 |
| 31 Dec 23 | 0 | -5 | 5 | 0 |
| 30 Sep 23 | 0 | -6 | 6 | 0 |
| 30 Jun 23 | 0 | -6 | 6 | 0 |
| 31 Mar 23 | 0 | -7 | 7 | 0 |
| 31 Dec 22 | 0 | -8 | 7 | 0 |
| 30 Sep 22 | 0 | -7 | 8 | 0 |
| 30 Jun 22 | 0 | -7 | 8 | 0 |
| 31 Mar 22 | 0 | -7 | 7 | 0 |
| 31 Dec 21 | 0 | -7 | 6 | 0 |
| 30 Sep 21 | 0 | -7 | 5 | 0 |
| 30 Jun 21 | 0 | -7 | 4 | 0 |
| 31 Mar 21 | 0 | -6 | 3 | 0 |
| 31 Dec 20 | 0 | -5 | 3 | 0 |
Quality Earnings: LLAI is currently unprofitable.
Growing Profit Margin: LLAI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LLAI is unprofitable, but has reduced losses over the past 5 years at a rate of 7% per year.
Accelerating Growth: Unable to compare LLAI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LLAI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Return on Equity
High ROE: LLAI has a negative Return on Equity (-56.31%), as it is currently unprofitable.